MX391574B - Partículas coloidales para su uso en medicina. - Google Patents

Partículas coloidales para su uso en medicina.

Info

Publication number
MX391574B
MX391574B MX2018004445A MX2018004445A MX391574B MX 391574 B MX391574 B MX 391574B MX 2018004445 A MX2018004445 A MX 2018004445A MX 2018004445 A MX2018004445 A MX 2018004445A MX 391574 B MX391574 B MX 391574B
Authority
MX
Mexico
Prior art keywords
medicine
colloidal particles
composition
contain
active agent
Prior art date
Application number
MX2018004445A
Other languages
English (en)
Other versions
MX2018004445A (es
Inventor
John Mayo
Richard Wolf-Garraway
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of MX2018004445A publication Critical patent/MX2018004445A/es
Publication of MX391574B publication Critical patent/MX391574B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona una composición que comprende una partícula coloidal que comprende aproximadamente del 0.5 al 20 por ciento en moles de un lípido anfipático derivatizado con un polímero hidrófilo biocompatible para su uso en medicina, en la que dicha composición no contiene ningún agente farmacéuticamente activo.
MX2018004445A 2015-10-14 2016-10-14 Partículas coloidales para su uso en medicina. MX391574B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518172.0A GB201518172D0 (en) 2015-10-14 2015-10-14 Colloidal particles for use in medicine
PCT/EP2016/074759 WO2017064276A1 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine

Publications (2)

Publication Number Publication Date
MX2018004445A MX2018004445A (es) 2018-08-14
MX391574B true MX391574B (es) 2025-03-21

Family

ID=55131025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004445A MX391574B (es) 2015-10-14 2016-10-14 Partículas coloidales para su uso en medicina.

Country Status (15)

Country Link
US (3) US20190192664A1 (es)
EP (1) EP3362039A1 (es)
JP (1) JP7160678B2 (es)
KR (1) KR20180067616A (es)
CN (1) CN108472246A (es)
AU (1) AU2016336929B2 (es)
BR (1) BR112018007399A2 (es)
CA (1) CA3036111C (es)
EA (1) EA201890703A1 (es)
GB (1) GB201518172D0 (es)
HK (1) HK1256814A1 (es)
IL (1) IL258567B2 (es)
MX (1) MX391574B (es)
SG (2) SG11201802956RA (es)
WO (1) WO2017064276A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220347113A1 (en) * 2019-11-07 2022-11-03 The Board Of Trustees Of The University Of Illinois Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation
GB202111759D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111758D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0713388B1 (en) 1993-08-06 1999-05-06 Opperbas Holding B.V. A method for high loading of vesicles with biopolymeric substances
DE69922189T2 (de) 1998-04-27 2005-11-10 Opperbas Holding B.V. Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
ATE317869T1 (de) 1999-07-14 2006-03-15 Alza Corp Neutrales lipopolymer und liposomale zusammensetzungen daraus
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
JP2006523683A (ja) 2003-04-15 2006-10-19 オッパーバス・ホールディング・ビー・ブイ タンパク質及び／またはポリペプチド及びコロイド粒子を含む医薬組成物
CA2613705A1 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic pr0tein-lip1d complexes
SG176297A1 (en) 2009-06-03 2012-01-30 John Charles Mayo Formulations for the treatment of deep tissue pain
SG178502A1 (en) 2009-08-21 2012-03-29 Targeted Delivery Technologies Ltd Vesicular formulations
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
EP2838566A2 (en) 2012-04-16 2015-02-25 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
KR102255108B1 (ko) * 2013-03-08 2021-05-24 노파르티스 아게 활성제의 전달을 위한 지질 및 지질 조성물

Also Published As

Publication number Publication date
JP2018535952A (ja) 2018-12-06
JP7160678B2 (ja) 2022-10-25
BR112018007399A2 (pt) 2018-10-16
CA3036111A1 (en) 2017-04-20
US20210093721A1 (en) 2021-04-01
AU2016336929A1 (en) 2018-05-10
MX2018004445A (es) 2018-08-14
IL258567A (en) 2018-05-31
AU2016336929B2 (en) 2022-09-29
KR20180067616A (ko) 2018-06-20
CA3036111C (en) 2023-06-06
IL258567B1 (en) 2025-04-01
SG10202010711UA (en) 2020-12-30
US20190192664A1 (en) 2019-06-27
WO2017064276A1 (en) 2017-04-20
IL258567B2 (en) 2025-08-01
CN108472246A (zh) 2018-08-31
SG11201802956RA (en) 2018-05-30
EP3362039A1 (en) 2018-08-22
US20250170244A1 (en) 2025-05-29
GB201518172D0 (en) 2015-11-25
HK1256814A1 (zh) 2019-10-04
EA201890703A1 (ru) 2018-11-30

Similar Documents

Publication Publication Date Title
SA520411636B1 (ar) صيغ جسيمات نانوية دهنية
CY1124380T1 (el) Συστηματα διαβλεννογονιας και διαδερμικης χορηγησης
MX384021B (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
MX2016014622A (es) Sistemas de suministro de medicamentos y metodos de uso relacionados.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
WO2016040887A3 (en) Multilamellar lipid vesicle compositions and methods of use
MX386234B (es) Vacuna para la malaria.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
MX382580B (es) Formulaciones de liberación inmediata disuasivas de abuso que comprenden polisacáridos no celulósicos.
MX391574B (es) Partículas coloidales para su uso en medicina.
MX2018005456A (es) Capsulas de liberación prolongada recubiertas con película.
MX2020007293A (es) Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.
SG10201902499VA (en) Therapeutic nanoparticles and related compositions, methods and systems
TWD174176S (zh) 給藥裝置之部分（二）
WO2014165513A3 (en) Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof
BR112017006918A2 (pt) formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
MX2017004378A (es) Formulaciones farmaceuticas de liposomas pegilados y factores de coagulacion sanguinea.
MX377823B (es) Composición nasal con capacidades de formación de película.
FI20155045A7 (fi) Havupuun pihka steriilin tulehduksen hoitamiseksi ja ennaltaehkäisemiseksi